Bavarian Nordic's Monkeypox Vaccine Scores EU Approval As WHO Declares Global Health Emergency

As the WHO declared the monkeypox outbreak a global health emergency, Bavarian Nordic A/S BVNRY obtained an expanded European label for its smallpox vaccine Imvanex, to include the surging monkeypox virus.
On Saturday, WHO officially declared the outbreak a global health emergency. Since then, the outbreak has continued to grow, and there are more than 16,000 reported cases from 75 countries and five deaths.
The approval follows a positive opinion by the Committee for Medicinal Products for Human Use (CHMP).
Also Read: Twist Bioscience Launches Monkeypox Virus Synthetic DNA Controls For Developing Assays.
“WHO’s assessment is that the risk of monkeypox is moderate globally and in all regions, except in the European region where we assess the risk as high,” WHO director-general Tedros Adhanom Ghebreyesus said.
“There is also a clear risk of further international spread, although the risk of interference with international traffic remains low for the moment,” added.
Related: Bavarian Nordic Inks Multiple Supply Pact For Its Monkeypox Vaccine, Updates FY22 Guidance.
Price Action: BVNRY shares traded 3.24% higher at $15.13 on the last check Monday.